All News
Links:
PMR & Popeye's Spinach (10.6.2023)
Dr. Jack Cush reviews the big PMR reports from this week along with other journal reports from RheumNow.com.
Read Article
RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)
This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?
Read Article
Uncertainty on Pre-Clinical RA – Rheumatologist Survey Results
In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.
Read Article
Advice on Multi-Drug Failures in RA
What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.
Read Article
Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring
We use biologic agents on a daily basis in the treatment of rheumatoid arthritis. Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment.
Read Article
TNR: Decisions in Methotrexate
This Tuesday Night Rheumatology panel discussion on "Methotrexate Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer.
Read Article
RA Associated Cancer Risk
A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.
Read Article
RheumNow Podcast – with Special Guest Dr. Peter Nash (9.15.2023)
This week, Dr. Jack Cush reviews the news with special guest, Dr. Peter Nash. They discuss COVID Autoantibodies, SpA life expectancy, HCQ, extraarticular RA and our approach to Early RA referrals and pre-clinical RA.
Read Article
Adalimumab Biosimilars: Realizing the Promise of Market Competition
Over four years after adalimumab biosimilars were first launched in the European Union and elsewhere, adalimumab biosimilars have finally become available in the United States.
Read Article
TNR: Early RA - Referrals and Treatment
This Tuesday Night Rheumatology was an hour long panel discussion featuring Drs. Jack Cush, Vivian Bykerk, Glen Hazelwood and Martin J. Bergman.
The Panel discussed Rheumatologists views on Early RA referral and intake, initial treatment preferences and views on diagnosing and treating pre-clinical RA.
RA Extra-articular Manifestations Declining
A Mayo Clinic population based cohort study shows the extraarticular manifestations of rheumatoid arthritis (ExRA) have declined with time; but the increased mortality risk of RA remains unchanged.
Read Article
Hydroxychloroquine Adherence Lowers Cardiovascular Risks
Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.
Read Article
RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)
This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".
Read Article
Woeful Rheumatology Referrals
Early diagnosis of inflammatory arthritis (IA) is rooted in patient (self or MD) referrals. A recent analysis shows only a minority of rheumatology referrals had inflammatory arthritis, with only 21% were seen within the first 6 weeks of symptoms.
Read Article
Oral Surveillance Changes in Advanced Therapy Use in RA
The safety of tofacitinib and TNF inhibitors was studied in high risk rheumatoid arthritis (RA) patients in the ORAL Surveillance study, which culminated in an FDA warning in January 2021 on the cardiovascular, cancer and VTE risks associated with JAK inhibitor use.
Read Article
Aortic Stenosis Risk in RA
A large cohort study has shown that rheumatoid arthritis (RA) patients are at an increased risk of developing aortic stenosis (AS), undergoing aortic valve intervention, or AS-related death.
Read Article
Hard Decisions in RA (9.1.2023)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".
Read Article